This study was planned to evaluate the clinical status of 33 patients with malignant ovarian tumors, who were admitted, operated, and confirmed histopathologically at the Department of Obstetrics and Gynecology, Ewha Womans University Hospital during the period of 5 years from January 1984 to December 1988.
The results were as follows :
1) The incidence of malignant ovarian tumors was 13.1% of all ovarian tumors.
2) The most common clinical symptom was palpable abdominal mass(54.5%), and the rest were abdominal discomfort(42.4%), abdominal distention(30.3%), and vaginal bleeding(24.2%) in that order.
The patients with malignant ovarian tumor were comprised of stage I(51.5%), stage II(15.2%), stage III(21.2%) and stage IV(12.1%).
3) According to histopathological classification, patients with epithelial tumor were 81.8%, and epithelial tumors were divided into the serous type(34.3%) and mucinous type(30.3%), undifferentiated type(12.1%), and endomentrioid type(6.1%), Other tumors were germ cell tumor(endodermal sinus tumor, malignant teratoma), granulosa cell tumor(endodermal sinus tumor, malignant teratoma), granulosa cell tumor, and Krukenberg tumor.
4) Operative methods for malignant ovarian tumor were total abdominal hysterectomy with bilateral salpingo-oophorectomy(24.3%), total abdominal hysterectomy, bilateral salpingo-oophorectomy with omentectomy(21.2%), and total abdominal hysterectomy, bilateral salpingo-oophorectomy with lymphnode biopsy(9.1%).
Postoperative chemotherapy for patients were done in 75.7% of patients, and 30.3% of patients with melphalan, 39.4% with combination therapy of cisplatinum-based regimen(aclacinon plus cyclophosphamide, cyclophosphamide, adriamycin, bleomycin).
5) 14 patients(42.4%) were alive in the follow-up period from less than 1 year to 5years and 11 patients were in stage I, 2 patients in stage II, and 1 patient in stage III.
12 patients(36.4%) were dead; 2 patients with stage I endodermal sinus tumor were dead within 6 months since the diagnosis was confirmed, 6 patients with stage III and 4 patients with stage IV were dead within 6-18 months.
